Good Growth Opportunities in Global Cancer Biological Therapy Market FMI Releases New Report on the Cancer Biological T | Page 3

Report
Description
Report Description
Biological cancer therapies use the body’s immune system, either directly or indirectly, to
fight cancer or to lessen the side effects that may be caused by some cancer treatments.
It is also called biotherapy or biological response modifiers. Interferons and monoclonal
antibodies are among the most promising biological approaches to cancer treatment.
Biological therapy works by stimulating, boosting, restoring or acting like the body’s
immune system response against cancer cells. Cancer is a leading cause of death
worldwide. Factors that contribute to geographic differences in cancer occurrence
include the prevalence of risk factors, the availability and use of diagnostic tests,
variations in the age structure of the population, and the availability and quality of
treatment. According to WHO, approximately 14 million new cases and 8.2 million cancer
related deaths in 2012. Tobacco use is the most important risk factor for cancer causing
around 20% of global cancer deaths and around 70% of global lung cancer deaths.
Cancer Biological Therapy Market: Drivers and Restraints
The factors such as growing prevalence of cancer, continuous patent expiry of cancer
drugs, rising impact of biosimilars and increasing demand of biological and targeted drug
therapies will drive the overall cancer biological therapy market. According to WHO, the
number of new cancer cases is projected to rise 70% in the coming two decades, mainly
due to increased use of tobacco and alcohol consumption. However, the threat of failure
in treatment, the high cost of drug development, the adverse effects of cancer drug
therapy, particularly chemotherapy and stricter government regulations will hinders the
overall cancer biological therapy market growth globally.